Myocardial bridging in obstructive hypertrophic cardiomyopathy: a risk factor for myocardial fibrosis.
Fibrosis
Hypertrophic cardiomyopathy
Myocardial bridging
Survival
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
27 Feb 2024
27 Feb 2024
Historique:
received:
26
09
2023
accepted:
12
02
2024
medline:
28
2
2024
pubmed:
28
2
2024
entrez:
27
2
2024
Statut:
epublish
Résumé
Myocardial bridging (MB) is common in patients with hypertrophic cardiomyopathy (HCM). There are sparse data on the impact of MB on myocardial fibrosis in HCM. This study was designed to evaluate the relationship between MB and myocardial fibrosis in patients with obstructive HCM. In this cohort study, retrospective data were collected from a high-volume HCM center. Patients with obstructive HCM who underwent septal myectomy and preoperative cardiac magnetic resonance (CMR) were screened from 2011 to 2018. Finally, 492 patients were included in this study, with an average age of 45.7 years. Of these patients, 76 patients had MB. MB occurred mostly in the left anterior descending artery (73/76). The global extent of late gadolinium enhancement (LGE) was correlated with the degree of systolic compression (r = 0.33, p = 0.003). Multivariable linear regression analysis revealed that the degree of systolic compression was an independent risk factor for LGE (β = 0.292, p = 0.007). The LGE fraction of basal and mid anteroseptal segments in patients with severe MB (compression ratio ≥ 80%) was significantly greater than that in patients with mild to moderate MB (compression ratio < 80%). During a median follow-up of 28 (IQR: 15-52) months, 15 patients died. Kaplan-Meier analysis did not identify differences in all-cause death (log-rank p = 0.63) or cardiovascular death (log-rank p = 0.72) between patients undergoing MB-related surgery and those without MB. MB with severe systolic compression was significantly associated with a high extent of fibrosis in patients with obstructive HCM. Concomitant myotomy or coronary artery bypass grafting might provide excellent survival similar to that of patients without MB. Identification of patients with severe MB and providing comprehensive management might help improve the prognosis of patients with HCM.
Sections du résumé
BACKGROUND
BACKGROUND
Myocardial bridging (MB) is common in patients with hypertrophic cardiomyopathy (HCM). There are sparse data on the impact of MB on myocardial fibrosis in HCM. This study was designed to evaluate the relationship between MB and myocardial fibrosis in patients with obstructive HCM.
METHODS
METHODS
In this cohort study, retrospective data were collected from a high-volume HCM center. Patients with obstructive HCM who underwent septal myectomy and preoperative cardiac magnetic resonance (CMR) were screened from 2011 to 2018.
RESULTS
RESULTS
Finally, 492 patients were included in this study, with an average age of 45.7 years. Of these patients, 76 patients had MB. MB occurred mostly in the left anterior descending artery (73/76). The global extent of late gadolinium enhancement (LGE) was correlated with the degree of systolic compression (r = 0.33, p = 0.003). Multivariable linear regression analysis revealed that the degree of systolic compression was an independent risk factor for LGE (β = 0.292, p = 0.007). The LGE fraction of basal and mid anteroseptal segments in patients with severe MB (compression ratio ≥ 80%) was significantly greater than that in patients with mild to moderate MB (compression ratio < 80%). During a median follow-up of 28 (IQR: 15-52) months, 15 patients died. Kaplan-Meier analysis did not identify differences in all-cause death (log-rank p = 0.63) or cardiovascular death (log-rank p = 0.72) between patients undergoing MB-related surgery and those without MB.
CONCLUSIONS
CONCLUSIONS
MB with severe systolic compression was significantly associated with a high extent of fibrosis in patients with obstructive HCM. Concomitant myotomy or coronary artery bypass grafting might provide excellent survival similar to that of patients without MB. Identification of patients with severe MB and providing comprehensive management might help improve the prognosis of patients with HCM.
Identifiants
pubmed: 38413945
doi: 10.1186/s12916-024-03301-6
pii: 10.1186/s12916-024-03301-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
86Subventions
Organisme : National High Level Hospital Clinical Research Funding of China
ID : 2022-GSP-TS-8
Organisme : Chongqing Municipal Key Research and Development Program of China
ID : 2020YFC1107204
Informations de copyright
© 2024. The Author(s).
Références
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e533–57. https://doi.org/10.1161/CIR.0000000000000938 .
doi: 10.1161/CIR.0000000000000938
pubmed: 33215938
Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(4):372–89. https://doi.org/10.1016/j.jacc.2021.12.002 .
doi: 10.1016/j.jacc.2021.12.002
pubmed: 35086660
Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379(7):655–68. https://doi.org/10.1056/NEJMra1710575 .
doi: 10.1056/NEJMra1710575
pubmed: 30110588
Sternheim D, Power DA, Samtani R, Kini A, Fuster V, Sharma S. Myocardial bridging: diagnosis, functional assessment, and management: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;78(22):2196–212. https://doi.org/10.1016/j.jacc.2021.09.859 .
doi: 10.1016/j.jacc.2021.09.859
pubmed: 34823663
Nie C, Zhu C, Yang Q, Xiao M, Meng Y, Wang S. Myocardial bridging of the left anterior descending coronary artery as a risk factor for atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy: a matched case–control study. BMC Cardiovasc Disord. 2021;21(1):382. https://doi.org/10.1186/s12872-021-02185-1 .
doi: 10.1186/s12872-021-02185-1
pubmed: 34362314
pmcid: 8348797
Bruce C, Ubhi N, McKeegan P, Sanders K. Systematic review and meta-analysis of cardiovascular consequences of myocardial bridging in hypertrophic cardiomyopathy. Am J Cardiol. 2023;188:110–9. https://doi.org/10.1016/j.amjcard.2022.10.059 .
doi: 10.1016/j.amjcard.2022.10.059
pubmed: 36512852
Tian T, Wang YL, Wang JZ, Sun K, Zou YB, Zhang WL, et al. Myocardial bridging as a common phenotype of hypertrophic cardiomyopathy has no effect on prognosis. Am J Med Sci. 2014;347(6):429–33. https://doi.org/10.1097/MAJ.0000000000000194 .
doi: 10.1097/MAJ.0000000000000194
pubmed: 24270076
Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79. https://doi.org/10.1093/eurheartj/ehu284 .
doi: 10.1093/eurheartj/ehu284
pubmed: 25173338
Sharzehee M, Chang Y, Song JP, Han HC. Hemodynamic effects of myocardial bridging in patients with hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2019;317(6):H1282–91. https://doi.org/10.1152/ajpheart.00466.2019 .
doi: 10.1152/ajpheart.00466.2019
pubmed: 31674812
Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, et al. Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy. JAMA Cardiol. 2019;4(7):644–57. https://doi.org/10.1001/jamacardio.2019.1391 .
doi: 10.1001/jamacardio.2019.1391
pubmed: 31116360
pmcid: 6537832
Hashi AA, Ramesh Prasad GV, Connelly PW, Deva DP, Nash MM, Yuan W, et al. Cardiac MRI assessment of the right ventricle preand postkidney transplant. Int J Cardiovasc Imaging. 2021;37(5):1757–66. https://doi.org/10.1007/s10554-020-02153-4 .
doi: 10.1007/s10554-020-02153-4
pubmed: 33475872
Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105(4):539–42. https://doi.org/10.1161/hc0402.102975 .
doi: 10.1161/hc0402.102975
pubmed: 11815441
Liu J, Zhao S, Yu S, Wu G, Wang D, Liu L, et al. Patterns of replacement fibrosis in hypertrophic cardiomyopathy. Radiology. 2022;302(2):298–306. https://doi.org/10.1148/radiol.2021210914 .
doi: 10.1148/radiol.2021210914
pubmed: 34726536
Zhang C, Liu R, Yuan J, Cui J, Hu F, Yang W, et al. Predictive values of N-terminal pro-B-type natriuretic peptide and cardiac troponin I for myocardial fibrosis in hypertrophic obstructive cardiomyopathy. PLoS One. 2016;11(1):e0146572. https://doi.org/10.1371/journal.pone.0146572 .
doi: 10.1371/journal.pone.0146572
pubmed: 26765106
pmcid: 4713160
Maron MS, Rowin EJ, Lin D, Appelbaum E, Chan RH, Gibson CM, et al. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2012;5(4):441–7. https://doi.org/10.1161/CIRCIMAGING.112.972760 .
doi: 10.1161/CIRCIMAGING.112.972760
pubmed: 22563033
Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation. 2003;108(19):2342–8. https://doi.org/10.1161/01.CIR.0000097110.55312.BF .
doi: 10.1161/01.CIR.0000097110.55312.BF
pubmed: 14581405
Basso C, Thiene G, Mackey-Bojack S, Frigo AC, Corrado D, Maron BJ. Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death. Eur Heart J. 2009;30(13):1627–34. https://doi.org/10.1093/eurheartj/ehp121 .
doi: 10.1093/eurheartj/ehp121
pubmed: 19406869
Yetman AT, McCrindle BW, MacDonald C, Freedom RM, Gow R. Myocardial bridging in children with hypertrophic cardiomyopathy–a risk factor for sudden death. N Engl J Med. 1998;339(17):1201–9. https://doi.org/10.1056/NEJM199810223391704 .
doi: 10.1056/NEJM199810223391704
pubmed: 9780340
Brodsky SV, Roh L, Ashar K, Braun A, Ramaswamy G. Myocardial bridging of coronary arteries: a risk factor for myocardial fibrosis? Int J Cardiol. 2008;124(3):391–2. https://doi.org/10.1016/j.ijcard.2006.12.062 .
doi: 10.1016/j.ijcard.2006.12.062
pubmed: 17399815
Yetman AT, Hamilton RM, Benson LN, McCrindle BW. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1998;32(7):1943–50. https://doi.org/10.1016/s0735-1097(98)00493-8 .
doi: 10.1016/s0735-1097(98)00493-8
pubmed: 9857876